Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with moderate-to-severe Crohn's Disease, confirmed through clinical assessment and/or internal camera examination or tissue analysis
- People who have previously been treated with a type of medication called a TNF inhibitor as their first treatment for Crohn's Disease for at least 6 months, with medical records available covering the past 2 years or from the start of that first treatment
Who may not be able to join:
- People whose health situation matches any of the warnings, precautions, or contraindications listed on the official approved labels for the study medications upadacitinib or risankizumab (confirm with trial site)
- People who have previously taken upadacitinib or risankizumab, or any other approved or investigational biologic medication for Crohn's Disease that is not a TNF inhibitor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: +39 06 548891
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants who Achieve Corticosteroids (CS) Free Remission
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.